Tests focused radiation for prostate cancer returning after surgery
Tests focused radiation against standard radiotherapy in men with rising PSA after surgery.
Plain-language title generated from the registry record
Registry title: Salvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence After Radical Prostatectomy.
Key facts
- Where
- Aalst, Antwerp, Bruges, Brussels, Genk, Ghent, Hasselt, Kortrijk, La Louvière, Leuven, Mechelen, Namur, and Woluwe-Saint-Lambert, BelgiumSee the 13 sites
Where in Belgium
- AZORGAalst, BelgiumTaking people
- Ziekenhuis Aan de Stroom (ZAS)Antwerp, BelgiumTaking people
- AZ Sint JanBruges, BelgiumTaking people
- Jules Bordet Institute, H.U.BBrussels, BelgiumTaking people
- Ziekenhuis Oost-Limburg (ZOL) Campus Sint-JanGenk, BelgiumTaking people
- UZ GentGhent, BelgiumTaking people
- JESSA ZiekenhuisHasselt, BelgiumTaking people
- AZ GroeningeKortrijk, BelgiumTaking people
- CHU HELORA - Hôpital de La Louvière - site JolimontLa Louvière, BelgiumTaking people
- UZ LeuvenLeuven, BelgiumTaking people
- AZ Sint MaartenMechelen, BelgiumTaking people
- CHU UCL Namur - Site ElisabethNamur, BelgiumTaking people
- Cliniques Universitaires Saint-Luc (UCLouvain)Woluwe-Saint-Lambert, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jules Bordet Institute
- Trial code
- NCT06523634
- Record updated
- 12 May 2026
- Original description
This is a a randomized phase II/III trial comparing salvage SBRT with standard of care (SOC) regimens for patients with a persistent detectable PSA or biochemical progression during follow-up after radical prostatectomy.Read full original descriptionShow less
Salvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence After Radical Prostatectomy.
This is a a randomized phase II/III trial comparing salvage SBRT with standard of care (SOC) regimens for patients with a persistent detectable PSA or biochemical progression during follow-up after radical prostatectomy.
Inclusion: Localized adenocarcinoma (cN0M0) of the prostate treated primarily with radical prostatectomy with definitive intent; Either persistent PSA after prostatectomy (PSA ≥ 0.1 ng/mL at least 6 weeks after prostatectomy), or biochemical progression (two consecutive rising PSA amounts with a PSA >0.1 ng/mL , or three consecutive PSA rises); WHO PS 0-1; Age ≥18 years; Ability to understand and willingness to sign a study-specific informed consent prior to study entry; Ability to understand and answer the EPIC-26 form in one of the languages available.
Exclusion: Patients with previously pathologically confirmed N1; Patients with macroscopically involved margin at surgery (R2); Prior history of high-intensity focused ultrasound ablation (HIFU), cryosurgery or brachytherapy of the prostate; Prior pelvic radiotherapy; Prior hormonal therapy started more than 6 weeks before randomization; History of inflammatory bowel disease, ataxia telangiectasia, prior rectal or bladder surgery; Patients with a history of distant metastases; Other active malignancy, except non-melanoma skin cancer, superficial bladder cancer, or malignancies with a documented disease-free survival for a minimum of 3 years before randomization; Patients with a pT4 tumor at prostatectomy; Patients with a recurrence visible on imaging (local, pelvic, or distant). Pelvic nodes with a small diameter >1cm and/or positive on PSMA without other explanation, are considered as a pelvic recurrence; Latest PSA > 2ng/ml; Patients with a IPSS >20; Gleason 10 tumor.